147 related articles for article (PubMed ID: 30808623)
1. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.
Poppelaars PBM; van Tuyl LHD; Boers M
Ann Rheum Dis; 2019 May; 78(5):586-589. PubMed ID: 30808623
[TBL] [Abstract][Full Text] [Related]
2. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.
Landewé RB; Boers M; Verhoeven AC; Westhovens R; van de Laar MA; Markusse HM; van Denderen JC; Westedt ML; Peeters AJ; Dijkmans BA; Jacobs P; Boonen A; van der Heijde DM; van der Linden S
Arthritis Rheum; 2002 Feb; 46(2):347-56. PubMed ID: 11840436
[TBL] [Abstract][Full Text] [Related]
3. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
Konijn NPC; van Tuyl LHD; Boers M; den Uyl D; Ter Wee MM; van der Wijden LKM; Bultink IEM; Kerstens PJSM; Voskuyl AE; van Schaardenburg D; Nurmohamed MT; Lems WF
Rheumatology (Oxford); 2017 Sep; 56(9):1586-1596. PubMed ID: 28859326
[TBL] [Abstract][Full Text] [Related]
4. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
[TBL] [Abstract][Full Text] [Related]
5. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis.
van Tuyl LH; Boers M; Lems WF; Landewé RB; Han H; van der Linden S; van de Laar M; Westhovens R; van Denderen JC; Westedt ML; Peeters AJ; Jacobs P; Huizinga TW; van de Brink H; Dijkmans BA; Voskuyl AE
Ann Rheum Dis; 2010 May; 69(5):807-12. PubMed ID: 19451137
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Verschueren P;
Rheumatology (Oxford); 2019 Dec; 58(12):2284-2294. PubMed ID: 31236568
[TBL] [Abstract][Full Text] [Related]
7. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Boers M; Verhoeven AC; Markusse HM; van de Laar MA; Westhovens R; van Denderen JC; van Zeben D; Dijkmans BA; Peeters AJ; Jacobs P; van den Brink HR; Schouten HJ; van der Heijde DM; Boonen A; van der Linden S
Lancet; 1997 Aug; 350(9074):309-18. PubMed ID: 9251634
[TBL] [Abstract][Full Text] [Related]
8. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
ter Wee MM; den Uyl D; Boers M; Kerstens P; Nurmohamed M; van Schaardenburg D; Voskuyl AE; Lems WF
Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis.
Boers M; van Tuyl L; van den Broek M; Kostense PJ; Allaart CF
Ann Rheum Dis; 2013 Mar; 72(3):406-9. PubMed ID: 23155223
[TBL] [Abstract][Full Text] [Related]
10. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
Pazmino S; Boonen A; Stouten V; De Cock D; Joly J; Van der Elst K; Westhovens R; Verschueren P
Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795
[TBL] [Abstract][Full Text] [Related]
11. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P
Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408
[TBL] [Abstract][Full Text] [Related]
12. [Combination therapy in early rheumatoid arthritis: the COBRA study].
Boers M; Verhoeven AC; van der Linden S
Ned Tijdschr Geneeskd; 1997 Dec; 141(50):2428-32. PubMed ID: 9555126
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoïde Artritis.
Verhoeven AC; Bibo JC; Boers M; Engel GL; van der Linden S
Br J Rheumatol; 1998 Oct; 37(10):1102-9. PubMed ID: 9825750
[TBL] [Abstract][Full Text] [Related]
15. Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis.
Rasch LA; van Tuyl LH; Lems WF; Boers M
Neuroimmunomodulation; 2015; 22(1-2):51-6. PubMed ID: 25227967
[TBL] [Abstract][Full Text] [Related]
16. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Verschueren P; Esselens G; Westhovens R
Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
[TBL] [Abstract][Full Text] [Related]
17. The COBRA trial 20 years later.
Boers M
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S46-51. PubMed ID: 22018183
[TBL] [Abstract][Full Text] [Related]
18. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
19. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.
Seegobin SD; Ma MH; Dahanayake C; Cope AP; Scott DL; Lewis CM; Scott IC
Arthritis Res Ther; 2014 Jan; 16(1):R13. PubMed ID: 24433430
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
